Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2024/2025 influenza season

as of February 6, 2026

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	3 (0.3%)	21 (1.0%)	21 (1.0%)	0	0	333 (100%)	2 (0.8%)	0	0	0	0	179 (100%)	0	0	0	0	0
Number of viruses tested	859	2,126	2,126	323	323	333	260	186	186	186	186	179	194	155	155	155	155
Number of viruses reported	3,866						648						647				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.